BRUTAFLAM-90 Etoricoxib Tablets 90mg

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

Etoricoxib

Boleh didapati daripada:

PAHANG PHARMACY SDN. BHD.

INN (Nama Antarabangsa):

Etoricoxib

Unit dalam pakej:

30 Tablets

Dikeluarkan oleh:

MANKIND PHARMA LTD (Unit-II)

Risalah maklumat

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
BRUTAFLAM
Etoricoxib Tablets 60mg, 90mg & 120mg
1
WHAT IS IN THIS LEAFLET?
1.
What BRUTAFLAM is used for
2.
How BRUTAFLAM works
3.
Before you use BRUTAFLAM
4.
How to use BRUTAFLAM
5.
While you are using it
6.
Side effects
7.
Storage
and
Disposal
of
BRUTAFLAM
8.
Product Description
9.
Manufacturer
and
Product
Registration Holder
10.
Date of revision
11.
Serial number
1.
WHAT BRUTAFLAM IS USED FOR
Your doctor has prescribed Brutaflam
tablet for:
•
treatment of osteoarthritis
•
treatment of rheumatoid arthritis
•
treatment of ankylosing spondylitis
•
treatment of acute pain after minor
dental procedures
•
treatment of menstrual pain
•
treatment of gout attacks
Osteoarthritis
is
a
joint
disease.
It
results from the gradual breakdown
of the cartilage that cushions the ends
of
the
bones,
resulting
in
pain,
inflammation,
tenderness,
stiffness,
and physical disability.
Rheumatoid
arthritis
is
a
chronic
disease
that
causes
pain,
stiffness,
swelling and loss of function in the
joints and inflammation in other body
organs.
Ankylosing
spondylitis
is
an
inflammatory disease of the spine and
large joints.
Gout is a disorder characterized by
sudden, recurring attacks of pain and
inflammation in one or more joints.
You may obtain further information
from your doctor or pharmacist, who
have more detailed information.
2.
HOW BRUTAFLAM WORKS
It
contains
a
medicine
called
Etoricoxib.
Brutaflam
tablet
is
a
member
of
a
group
of
medicines
called
selective
COX-2
inhibitors
that
are
used
to
reduce
pain
and
inflammation.
Brutaflam
tablet
is
not a narcotic.
3.
BEFORE YOU USE BRUTAFLAM
-
_When you must not use it _
Do not take Brutaflam tablet if you:
•
are allergic to any of its ingredients.
•
have
had
heart
failure,
a
heart
attack, bypass surgery, chest pain,
narrow or blocked arteries of the
extremities, a stroke or mini stroke
•
have high blood pressure that has
not been controlled by treatment
If you are not sure, talk to your
doctor, nurse or pharmacist before
taking

Ciri produk

BRUTAFLAM
(ETORICOXIB TABLETS)
PRODUCT NAME
BRUTAFLAM-60
(Etoricoxib Tablets 60mg)
BRUTAFLAM-90
(Etoricoxib Tablets 90mg)
BRUTAFLAM-120
(Etoricoxib Tablets 120mg)
NAME AND STRENGTH OF ACTIVE SUBSTANCE(S)
Each film coated tablet contains 60, 90 or 120 mg of Etoricoxib
_List of Excipients _
_Core :_
Calcium Hydrogen Phosphate Anhydrous, Croscarmellose Sodium, Magnesium
Stearate, Microcrystalline Cellulose,
Hypromellose and Purified Water.
_Tablet Coating:_
Hypromellose, Lactose Monohydrate,Titanium Dioxide, Triacetin.
The 60 and 120 mg Tablets also contains Indigo Carmine Aluminum Lake
and Iron Oxide Yellow.
PRODUCT DESCRIPTION
Film-coated tablets.
BRUTAFLAM-60:
Dark-green colored, round shaped, biconvex film coated tablet plain on
both sides.
BRUTAFLAM-90:
White, round shaped, biconvex, bevelled edge, film coated tablet plain
on both sides.
BRUTAFLAM-120:
Pale-green colored, round shaped, biconvex film coated tablet plain on
both sides.
PHARMACOLOGICAL PROPERTIES
_PHARMACODYNAMICS_
Pharmacotherapeutic group: Anti-inflammatory and antirheumatic
products, non-steroids, coxibs, ATC code: M01AH05
Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) that
exhibits anti-inflammatory, analgesic, and antipyretic
activities in animal models. Etoricoxib is a potent, orally active,
highly selective cyclooxygenase-2 (COX-2) inhibitor within
and above the clinical dose range. Two isoforms of cyclooxygenase have
been identified: cyclooxygenase-1 (COX-1) and
cyclooxygenase-2 (COX-2). COX-1 is responsible for
prostaglandin-mediated normal physiologic functions such as gastric
cytoprotection and platelet aggregation. Inhibition of COX-1 by
nonselective NSAIDs has been associated with gastric damage
and platelet inhibition. COX-2 has been shown to be primarily
responsible for the synthesis of prostanoid mediators of pain,
inflammation, and fever. Selective inhibition of COX-2 by etoricoxib
decreases these clinical signs and symptoms with
decreased GI toxicity and without effects on platelet function.
Across clinical pharmacol